[Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
p53 protein overexpression was found to induce the production of antibodies in patient serum and, recently, the easy detection of serum antibodies has been made possible. The aim of this study is to determine the significance of serum p53 antibodies in patients with primary colorectal adenocarcinoma in comparison with their clinicopathological features, and the tumor marker sensitivities of carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA19-9) and alpha-fetoprotein (AFP). Thirty-nine of 86 patients (45.3%) were positive for serum p53 antibodies. However, there was no relation with the cancer progression or clinicopathological findings. The sensitivities of CEA, CA19-9 and AFP were 36.0%, 38.4%, and 8.1% respectively, but there was no relation between serum p53 antibodies and these three markers. When the sensitivity of serum p53 antibodies and CEA was evaluated according to clinical stage, the presence of serum p53 antibodies was more significantly associated with stage 0, I and II colorectal cancer than was CEA. Thirty-three patients who showed preoperative positivity for serum p53 antibodies were followed by serial evaluation of circulating antibodies after resection. Negative conversions after resection were significantly higher in the "Cur A" group than in the "Cur B" or "Cur C" groups. Serum p53 antibodies appear to be a useful tumor marker independent of the other markers, especially in the early stage, and are expected to be useful in the development of a method of early diagnosis for mass screening, and as a postoperative monitoring marker for colorectal cancer.
Takeda
A
A
Second Dept. of Surgery, School of Medicine, Chiba University.
Shimada
H
H
Nakajima
K
K
Imaseki
H
H
Okazumi
S
S
Takayama
W
W
Hayashi
H
H
Iwasaki
K
K
Sasagawa
S
S
Chou
A
A
Natsume
T
T
Kouno
T
T
Kondou
S
S
Maeda
T
T
Hori
S
S
Suzuki
T
T
Ochiai
T
T
Isono
K
K
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D003110:Colonic Neoplasms / Q000276:immunology* / Q000601:surgery; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015166:Monitoring, Immunologic; D011184:Postoperative Period; D012004:Rectal Neoplasms / Q000276:immunology* / Q000601:surgery; D012680:Sensitivity and Specificity; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*; D000509:alpha-Fetoproteins / Q000032:analysis
D000906:Antibodies; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D016159:Tumor Suppressor Protein p53; D000509:alpha-Fetoproteins